

Cell Line Information Sheet for MM603

Cell Line Designation MM603

CellBank Catalogue No. CBA-1359

> **Lot Number** 13591010G

Passage Number +11

 $2.5 \times 10^{6} \text{ cells}$ **Total Cell Number**

91% **Expected Cell Viability**


> **Brief Description** Melanoma from metastatic site

> > **Organism** Human (Homo Sapiens)

> > > **Tissue** Skin

Growth Properties Adherent

> Morphology **Epithelial**



Image

Growth Medium

RPMI 1640 (with 2mM L-Glutamine+25mM Hepes) +10%FBS

Split sub-confluent flasks (70-80%). Optimal split ratio 1:4 using 0.05% Trypsin/EDTA at 37°C for 5 minutes. Seeding density

 $1.2 \times 10^4 \text{ cells/cm}^2$

Subcultivation Ratio

Establishing and Maintaining your Culture Cells incubated at 37°C with 5% CO₂.

Please refer to Technical & Customer Service Information

pamphlet for further information..

Cryoprotectant Medium

10% DMSO + 90% FCS.



Cell Line Information Sheet for MM603

Safety Precaution

Where cell lines are shipped as frozen ampoules there is a small risk that the ampoule may be pressurised, due to the expansion of trapped liquid nitrogen and could explode on warming. It is recommended that persons handling ampoules of frozen cells wear appropriate personal protective equipment including laboratory coat, insulated gloves and a full protective face shield.

Biosafety Level.

Cell line of human origin. CellBank Australia recommends that cell lines be handled at category PC-2* containment level.

*AS/NZS 2243.3:2010

Handling Procedure for Frozen Cells

Upon receipt, frozen ampoules should be transferred directly to liquid nitrogen storage without delay, if not to be used immediately. Storage at -80°C may result in loss of viability. Remove protective cryoflex layer around the ampoule prior to thawing. A precentrifugation step to remove the cryoprotectant after thawing is necessary for this cell line.

Use Restrictions

These cells are distributed for research purposes only - refer to the Material Transfer Agreement (MTA).

Additional Information

Mutations

V599E BRAF Peter Parsons

Depositor

Queensland Institute of Medical Research. Australia

Castellano M *et al.*CDKN2A/p16 Is Inactivated in Most Melanoma Cell Lines Cancer Research 57: 4868-4875, 1997

Pavey S *et al*. Microarray expression profiling in melanoma reveals a BRAF mutation signature Oncogene 23: 4060–4067, 2004

References

Packer L. *et al.* Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN Carcinogenesis 27: (9) 1778-1786, 2006

Mitchell Stark and Nicholas Hayward Genome-Wide Loss of Heterozygosity and Copy Number Analysis in Melanoma Using High-Density Single-Nucleotide Polymorphism Arrays Cancer

Research 67: (6).2632-2642, 2007

While CellBank Australia uses reasonable efforts to include accurate and up-to date information on this product sheet, CellBank Australia makes no warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. CellBank Australia does not warrant that such information has been confirmed to be accurate.

CellBank Warranty



Cell Line Information Sheet for MM603

Disclaimers

This product is sent with the condition that you are responsible for its safe storage, handling, and use. CellBank Australia is not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to insure authenticity and reliability of strains on deposit, CellBank Australia is not liable for damages arising from the misidentification or misrepresentation of cultures.

Please refer to the MTA for further details regarding the use of this product. The MTA is also available on our Web site at www.cellbankaustralia.com